Image

Global Prophylaxis of Organ Rejection Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Prophylaxis of Organ Rejection Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Global
  • 350 Pages
  • No of Tables: 1001
  • No of Figures: 84

Global Prophylaxis of Organ Rejection Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 2,781.83 USD Million
Diagram Market Size (Forecast Year) USD 3,894.40 USD Million
Diagram CAGR %

Major Markets Players

  • Ossium Health
  • Alphamab Oncology
  • Altavant Sciences
  • Hansa Biopharma
  • Concord Biotech

Global Prophylaxis Of Organ Rejection Market, By Cause (Epidemiologic Exposure, Antibacterial Prophylaxis, Prophylaxis Against Other Pathogens And Others), Treatment (Outpatient Immunosuppressant, Inpatient Immunosuppressant And Others), Route Of Administration (Oral, Intravenous), Organ (Kidney, Liver, Heart, Lung, Others), Patient Type (Pediatric, Adults), End User (Hospitals, Clinic Home Healthcare And Others), Distribution Channel (Direct Tender, Pharmacy Stores And Others), Country (U.S., Canada & Mexico, Germany, France, U.K., Italy, Spain, Russia, Belgium, Turkey, Switzerland, Netherlands, And Rest Of Europe, Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines & Rest Of Asia-Pacific, Brazil, Argentina & Rest Of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt & Rest Of Middle East And Africa). Industry Trends and Forecast to 2029.

Prophylaxis of Organ Rejection Market

Market Analysis and Insights: Global Prophylaxis of Organ Rejection Market

Global prophylaxis of organ rejection market is expected to gain market growth in the forecast period of 2020 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.4% in the forecast period of 2022 to 2029 and is expected to reach USD 3,894.40 million by 2029 from USD 2,781.83 million in 2021. The rising prevalence of organ transplantation and increased use of immunosuppressant are likely to be the major drivers which propel the demand of the market in the forecast period.

The term prophylaxis means treatment given or action taken to prevent disease. The prophylaxis of organ rejection, refers to the prevention of organ rejection by use of medicines. The patients who undergo transplantation, must be maintained on an immunosuppression regimen for rejection prophylaxis to help ensure graft survival. The transplant rejection is a process, in which a transplant recipient’s immunity the current rejection prophylaxis implements use of calcineurin inhibitors, mTOR inhibitors, antimetabolite agents, and corticosteroids. The treatment agents improve the short term consequences of the organ transplantation, but certain improvements. The recipient patients, who have undergone solid organ transplantation, should take anti-rejection medicines. This is because the immunity system would destroy the transplanted organ.

The driving factors responsible for the growth of the global prophylaxis of organ rejection market are the increased prevalence of organ transplantation, rise in surgical procedures, rise in recipient population and product launches. However, the factors that are expected to restrain the market are the rise in the cost of the transplantation procedure, lack of awareness about organ transplantation and the risks included while the patient receives the transplanted organ.

  • On the other hand, strategic initiatives by market players, rise in research and developments and use of immunosuppressant may act as an opportunity for the growth of the global prophylaxis of organ rejection market. The need for skilled expertise and the regulatory approval may create challenges for the global prophylaxis of organ rejection market. There are recent developments related to the global prophylaxis of organ rejection market.

Global prophylaxis of organ rejection market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Prophylaxis of Organ Rejection Market

Global Prophylaxis of Organ Rejection Market Scope and Market Size

Global prophylaxis of organ rejection market is categorized into seven segments cause, treatment, route of administration, organ, patient type, end user and distribution channel.

  • On the basis of cause, the global prophylaxis of organ rejection market is segmented into epidemiologic exposure, antibacterial prophylaxis, prophylaxis against other pathogens and others. In 2022, the epidemiologic exposure segment is expected to dominate the Global prophylaxis of organ rejection market due to availability of direct information and presence of pathogens related to prophylaxis of organ rejection in the U.S.
  • On the basis of treatment, the global prophylaxis of organ rejection market is segmented into outpatient immunosuppressant, inpatient immunosuppressant and others. In 2022, the outpatient immunosuppressant segment is expected to dominate the global prophylaxis of organ rejection market, since it can achieve the sustained and specific immune response against damaged cells and availability of cyclosporine in the U.S. and Canada.
  • On the basis of route of administration, the global prophylaxis of organ rejection market is segmented into oral and intravenous. In 2022, the oral segment is expected to dominate the Global prophylaxis of organ rejection due to increased availability and intake of oral tablets and capsules.
  • On the basis of organ, the global prophylaxis of organ rejection market is segmented into kidney, liver, heart, lung and others. In 2022, the kidney segment is expected to dominate the global prophylaxis of organ rejection due to increased incidence of kidney failure and presence of reimbursement policies such as Medicare, for the recipient’s insurance.
  • On the basis of patient type, the global prophylaxis of organ rejection market is segmented into pediatric and adults. In 2022, the adults segment is expected to dominate the global prophylaxis of organ rejection market, due to increased prevalence of chronic diseases and genetic conditions of the adult patients, weak immune system in adults and waiting list of adult recipients more than the waiting list of children and women.
  • On the basis of end user, the global prophylaxis of organ rejection market is segmented into hospitals, clinics, home healthcare and others. In 2022, the hospitals segment is expected to dominate the global prophylaxis of organ rejection market due to rise in medical care and collaboration with other hospitals in global for delivery of the donor organs to the recipient patients are predicted to dominate the market.
  • On the basis of distribution channel, the global prophylaxis of organ rejection market is segmented into direct tenders, pharmacy stores and others. In 2022, the direct tenders segment is expected to dominate the global prophylaxis of organ rejection market due to surge in demand of outpatient immunosuppressant by pharmaceutical companies and guaranteed payment, are predicted to dominate the market.

Prophylaxis of Organ Rejection Market

 Global Prophylaxis of Organ Rejection Market Country Level Analysis

Global prophylaxis of organ rejection market is categorized into seven segments cause, treatment, route of administration, organ, patient type, end user and distribution channel .

The countries covered in the prophylaxis of organ rejection market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Lithuania, rest of Europe in Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific(APAC) Brazil, Argentina, Peru, rest of South America in South America, South Africa, Saudi Arabia, UAE, Israel, Egypt, Kuwait and rest of Middle East and Africa in Middle East and Africa (MEA).

  • In 2022, the U.S. is dominating due to the presence of the largest consumer market with high GDP, due to the presence of major market players and increased technological advancement in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

U.S. is dominating the global prophylaxis of organ rejection in the global region due to presence of FDA approved medicines, presence of health remuneration policies, rise in prevalence of chronic diseases and rise in elderly population. The epidemiologic exposure segment is dominating the U.S., due to availability of direct information and understanding about the epidemiologic exposures and the net state of immune suppression, in the recipient patients in the U.S. Whereas, Germany is dominating the global prophylaxis of organ rejection in the Europe region due to presence of untapped opportunities in Germany for organ transplantation The epidemiologic exposure segment is expected to dominate the market since it can estimate the frequency of the organ rejection. Additionally, Japan is dominating the global prophylaxis of organ rejection in the Asia Pacific region due to favourable reimbursement scenario in Japan. The epidemiologic exposure segment is expected to dominate the market due to improvement in healthcare architecture in Japan and collaborations between healthcare organizations and market players to find associations, suggesting the potential cause of weak immune system responsible for organ rejection.

Growth Potential of the Prophylaxis of Organ Rejection in Emerging Economies and the Strategic Initiatives by Market Players are Creating New Opportunities in the Global Prophylaxis of Organ Rejection Market

Global prophylaxis of organ rejection market also provides you with detailed market analysis for every country growth in particular industry with wound debridement device sales, impact of advancement in the prophylaxis of organ rejection and changes in regulatory scenarios with their support for the prophylaxis of organ rejection market. The data is available for historic period 2020 to 2021.

Competitive Landscape and Global prophylaxis of Organ Rejection Market Share Analysis

Global prophylaxis of organ rejection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the prophylaxis of organ rejection market.

The major companies providing the global prophylaxis of organ rejection are Ossium Health, Inc, Alphamab Oncology, Altavant Sciences, Inc, Hansa Biopharma, Concord Biotech, Panacea Biotec, WOCKHARDT, SEBELA PHARMACEUTICALS, Accord-UK Ltd, Veloxis Pharmaceuticals, Inc, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy’s Laboratories, Ltd, Viatris Inc, Strides Pharma Science Limited, Glenmark, Biocon, Pfizer Inc, Mayne Pharma Group Limited ,Hikma Pharmaceuticals PLC, AbbVie Inc, Apotex Inc, Teva Pharmaceutical U.S.A Inc, Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Novitium Pharma, ZHEJIANG HISUN PHARMACEUTICAL Co., LTD, F. Hoffmann-La Roche Ltd, CSL Behring among others.

The strategic initiatives by market players along with new technological advancements for prophylaxis of organ rejection is bridging the gap for the prophylaxis of the organ rejection.

For instance,

  • In January 2020, Altavant Sciences, Inc, had acquired Onspira Therapeutics. Altavant Sciences Inc had developed OSP-101 for the treatment of bronchiolitis obliterans syndrome, the leading cause of morbidity and mortality in post-lung transplant patients. The acquisition would expand the product portfolio and to include OSP-101, for post market approval

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the global prophylaxis of organ rejection market which also provides the benefit for organisation to improve their offering for treatment products.


SKU-

TABLE 1 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 2 GLOBAL EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 GLOBAL EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 4 GLOBAL ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 GLOBAL ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 6 GLOBAL PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 GLOBAL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 GLOBAL OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 GLOBAL OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 23 GLOBAL ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 GLOBAL ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 GLOBAL TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 26 GLOBAL INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 28 GLOBAL KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 GLOBAL LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 GLOBAL HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 GLOBAL LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 GLOBAL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 34 GLOBAL ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 GLOBAL PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 37 GLOBAL HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 GLOBAL CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 GLOBAL HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 GLOBAL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 GLOBAL DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 GLOBAL PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 44 GLOBAL PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 GLOBAL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 46 GLOBAL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA PROPHYLAXIS OF ORGAN TRANSPLANT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 NORTH AMERICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 NORTH AMERICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 NORTH AMERICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 56 NORTH AMERICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 57 NORTH AMERICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 58 NORTH AMERICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 NORTH AMERICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 60 NORTH AMERICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 61 NORTH AMERICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 62 NORTH AMERICA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 63 NORTH AMERICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 64 NORTH AMERICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 65 NORTH AMERICA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 66 NORTH AMERICA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 67 NORTH AMERICA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 NORTH AMERICA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 NORTH AMERICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 70 U.S. PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 71 U.S. EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 72 U.S. ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 73 U.S. PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 U.S. OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 U.S. CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 U.S. TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 U.S. MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 U.S. MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 U.S. CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 U.S. INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 U.S. OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 U.S. ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 U.S. ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 U.S. PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 85 U.S. ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 86 U.S. TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 87 U.S. PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 88 U.S. PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 89 U.S. PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 90 U.S. PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 U.S. PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 92 CANADA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 93 CANADA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 94 CANADA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 95 CANADA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 CANADA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 97 CANADA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 CANADA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 99 CANADA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 100 CANADA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 CANADA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 CANADA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 CANADA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 CANADA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 CANADA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 106 CANADA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 107 CANADA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 108 CANADA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 109 CANADA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 110 CANADA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 111 CANADA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 112 CANADA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 113 CANADA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 114 MEXICO PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 115 MEXICO EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 116 MEXICO ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 117 MEXICO PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 MEXICO OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 MEXICO CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 MEXICO TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 MEXICO MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 MEXICO MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 MEXICO CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 MEXICO INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 MEXICO OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 126 MEXICO ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 127 MEXICO ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 128 MEXICO PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 129 MEXICO ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 130 MEXICO TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 131 MEXICO PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 132 MEXICO PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 133 MEXICO PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 134 MEXICO PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 135 MEXICO PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 136 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 137 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 138 EUROPE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 139 EUROPE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 140 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 EUROPE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 EUROPE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 143 EUROPE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 144 EUROPE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 145 EUROPE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 146 EUROPE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 147 EUROPE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 148 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 EUROPE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 150 EUROPE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 151 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 152 EUROPE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 153 EUROPE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 154 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 155 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 156 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 157 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 158 EUROPE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 159 FRANCE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 160 FRANCE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 161 FRANCE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 162 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 163 FRANCE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 164 FRANCE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 165 FRANCE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 166 FRANCE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 167 FRANCE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 168 FRANCE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 169 FRANCE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 170 FRANCE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 171 FRANCE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 172 FRANCE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 173 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 174 FRANCE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 175 FRANCE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 176 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 177 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 178 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 179 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 180 FRANCE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 181 SPAIN PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 182 SPAIN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 183 SPAIN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 184 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 185 SPAIN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 186 SPAIN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 187 SPAIN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 188 SPAIN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 189 SPAIN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 190 SPAIN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 191 SPAIN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 192 SPAIN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 193 SPAIN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 194 SPAIN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 195 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 196 SPAIN ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 197 SPAIN TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 198 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 199 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 200 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 201 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 202 SPAIN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 203 U.K. PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 204 U.K. EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 205 U.K. ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 206 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 207 U.K. OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 208 U.K. CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 209 U.K. TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 210 U.K. MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 211 U.K. MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 212 U.K. CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 213 U.K. INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 214 U.K. OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 215 U.K. ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 216 U.K. ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 217 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 218 U.K. ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 219 U.K. TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 220 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 221 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 222 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 223 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 224 U.K. PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 225 ITALY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 226 ITALY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 227 ITALY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 228 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 229 ITALY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 230 ITALY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 231 ITALY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 232 ITALY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 233 ITALY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 234 ITALY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 235 ITALY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 236 ITALY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 237 ITALY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 238 ITALY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 239 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 240 ITALY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 241 ITALY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 242 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 243 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 244 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 245 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 246 ITALY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 247 GERMANY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 248 GERMANY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 249 GERMANY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 250 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 251 GERMANY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 252 GERMANY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 253 GERMANY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 254 GERMANY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 255 GERMANY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 256 GERMANY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 257 GERMANY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 258 GERMANY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 259 GERMANY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 260 GERMANY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 261 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 262 GERMANY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 263 GERMANY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 264 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 265 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 266 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 267 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 268 GERMANY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 269 POLAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 270 POLAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 271 POLAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 272 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 273 POLAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 274 POLAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 275 POLAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 276 POLAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 277 POLAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 278 POLAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 279 POLAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 280 POLAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 281 POLAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 282 POLAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 283 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 284 POLAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 285 POLAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 286 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 287 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 288 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 289 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 290 POLAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 291 NETHERLANDS PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 292 NETHERLANDS EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 293 NETHERLANDS ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 294 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 295 NETHERLANDS OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 296 NETHERLANDS CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 297 NETHERLANDS TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 298 NETHERLANDS MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 299 NETHERLANDS MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 300 NETHERLANDS CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 301 NETHERLANDS INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 302 NETHERLANDS OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 303 NETHERLANDS ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 304 NETHERLANDS ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 305 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 306 NETHERLANDS ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 307 NETHERLANDS TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 308 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 309 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 310 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 311 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 312 NETHERLANDS PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 313 SWEDEN PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 314 SWEDEN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 315 SWEDEN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 316 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 317 SWEDEN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 318 SWEDEN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 319 SWEDEN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 320 SWEDEN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 321 SWEDEN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 322 SWEDEN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 323 SWEDEN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 324 SWEDEN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 325 SWEDEN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 326 SWEDEN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 327 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 328 SWEDEN ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 329 SWEDEN TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 330 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 331 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 332 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 333 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 334 SWEDEN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 335 AUSTRIA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 336 AUSTRIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 337 AUSTRIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 338 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 339 AUSTRIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 340 AUSTRIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 341 AUSTRIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 342 AUSTRIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 343 AUSTRIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 344 AUSTRIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 345 AUSTRIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 346 AUSTRIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 347 AUSTRIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 348 AUSTRIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 349 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 350 AUSTRIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 351 AUSTRIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 352 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 353 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 354 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 355 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 356 AUSTRIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 357 SWITZERLAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 358 SWITZERLAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 359 SWITZERLAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 360 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 361 SWITZERLAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 362 SWITZERLAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 363 SWITZERLAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 364 SWITZERLAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 365 SWITZERLAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 366 SWITZERLAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 367 SWITZERLAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 368 SWITZERLAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 369 SWITZERLAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 370 SWITZERLAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 371 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 372 SWITZERLAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 373 SWITZERLAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 374 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 375 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 376 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 377 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 378 SWITZERLAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 379 NORWAY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 380 NORWAY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 381 NORWAY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 382 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 383 NORWAY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 384 NORWAY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 385 NORWAY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 386 NORWAY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 387 NORWAY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 388 NORWAY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 389 NORWAY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 390 NORWAY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 391 NORWAY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 392 NORWAY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 393 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 394 NORWAY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 395 NORWAY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 396 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 397 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 398 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 399 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 400 NORWAY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 401 HUNGARY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 402 HUNGARY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 403 HUNGARY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 404 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 405 HUNGARY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 406 HUNGARY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 407 HUNGARY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 408 HUNGARY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 409 HUNGARY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 410 HUNGARY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 411 HUNGARY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 412 HUNGARY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 413 HUNGARY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 414 HUNGARY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 415 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 416 HUNGARY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 417 HUNGARY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 418 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 419 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 420 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 421 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 422 HUNGARY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 423 DENMARK PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 424 DENMARK EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 425 DENMARK ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 426 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 427 DENMARK OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 428 DENMARK CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 429 DENMARK TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 430 DENMARK MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 431 DENMARK MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 432 DENMARK CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 433 DENMARK INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 434 DENMARK OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 435 DENMARK ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 436 DENMARK ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 437 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 438 DENMARK ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 439 DENMARK TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 440 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 441 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 442 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 443 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 444 DENMARK PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 445 IRELAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 446 IRELAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 447 IRELAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 448 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 449 IRELAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 450 IRELAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 451 IRELAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 452 IRELAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 453 IRELAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 454 IRELAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 455 IRELAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 456 IRELAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 457 IRELAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 458 IRELAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 459 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 460 IRELAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 461 IRELAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 462 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 463 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 464 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 465 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 466 IRELAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 467 GREECE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 468 GREECE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 469 GREECE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 470 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 471 GREECE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 472 GREECE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 473 GREECE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 474 GREECE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 475 GREECE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 476 GREECE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 477 GREECE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 478 GREECE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 479 GREECE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 480 GREECE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 481 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 482 GREECE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 483 GREECE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 484 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 485 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 486 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 487 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 488 GREECE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 489 LITHUANIA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 490 LITHUANIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 491 LITHUANIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 492 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 493 LITHUANIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 494 LITHUANIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 495 LITHUANIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 496 LITHUANIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 497 LITHUANIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 498 LITHUANIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 499 LITHUANIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 500 LITHUANIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 501 LITHUANIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 502 LITHUANIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 503 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 504 LITHUANIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 505 LITHUANIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 506 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 507 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 508 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 509 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 510 LITHUANIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 511 REST OF EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 512 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 513 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 514 ASIA-PACIFIC EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 515 ASIA-PACIFIC ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 516 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 517 ASIA-PACIFIC OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 518 ASIA-PACIFIC CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 519 ASIA-PACIFIC TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 520 ASIA-PACIFIC MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 521 ASIA-PACIFIC MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 522 ASIA-PACIFIC CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 523 ASIA-PACIFIC INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 524 ASIA-PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 525 ASIA-PACIFIC ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 526 ASIA-PACIFIC ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 527 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 528 ASIA-PACIFIC ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 529 ASIA-PACIFIC TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 530 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 531 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 532 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 533 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 534 ASIA-PACIFIC PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 535 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 536 CHINA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 537 CHINA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 538 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 539 CHINA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 540 CHINA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 541 CHINA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 542 CHINA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 543 CHINA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 544 CHINA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 545 CHINA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 546 CHINA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 547 CHINA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 548 CHINA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 549 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 550 CHINA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 551 CHINA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 552 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 553 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 554 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 555 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 556 CHINA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 557 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 558 JAPAN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 559 JAPAN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 560 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 561 JAPAN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 562 JAPAN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 563 JAPAN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 564 JAPAN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 565 JAPAN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 566 JAPAN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 567 JAPAN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 568 JAPAN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 569 JAPAN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 570 JAPAN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 571 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 572 JAPAN ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 573 JAPAN TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 574 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 575 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 576 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 577 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 578 JAPAN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 579 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 580 SOUTH KOREA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 581 SOUTH KOREA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 582 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 583 SOUTH KOREA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 584 SOUTH KOREA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 585 SOUTH KOREA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 586 SOUTH KOREA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 587 SOUTH KOREA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 588 SOUTH KOREA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 589 SOUTH KOREA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 590 SOUTH KOREA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 591 SOUTH KOREA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 592 SOUTH KOREA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 593 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 594 SOUTH KOREA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 595 SOUTH KOREA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 596 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 597 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 598 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 599 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 600 SOUTH KOREA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 601 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 602 INDIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 603 INDIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 604 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 605 INDIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 606 INDIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 607 INDIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 608 INDIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 609 INDIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 610 INDIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 611 INDIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 612 INDIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 613 INDIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 614 INDIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 615 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 616 INDIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 617 INDIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 618 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 619 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 620 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 621 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 622 INDIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 623 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 624 AUSTRALIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 625 AUSTRALIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 626 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 627 AUSTRALIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 628 AUSTRALIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 629 AUSTRALIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 630 AUSTRALIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 631 AUSTRALIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 632 AUSTRALIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 633 AUSTRALIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 634 AUSTRALIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 635 AUSTRALIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 636 AUSTRALIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 637 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 638 AUSTRALIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 639 AUSTRALIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 640 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 641 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 642 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 643 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 644 AUSTRALIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 645 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 646 THAILAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 647 THAILAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 648 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 649 THAILAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 650 THAILAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 651 THAILAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 652 THAILAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 653 THAILAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 654 THAILAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 655 THAILAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 656 THAILAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 657 THAILAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 658 THAILAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 659 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 660 THAILAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 661 THAILAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 662 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 663 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 664 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 665 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 666 THAILAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 667 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 668 MALAYSIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 669 MALAYSIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 670 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 671 MALAYSIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 672 MALAYSIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 673 MALAYSIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 674 MALAYSIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 675 MALAYSIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 676 MALAYSIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 677 MALAYSIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 678 MALAYSIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 679 MALAYSIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 680 MALAYSIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 681 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 682 MALAYSIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 683 MALAYSIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 684 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 685 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 686 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 687 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 688 MALAYSIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 689 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 690 PHILIPPINES EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 691 PHILIPPINES ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 692 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 693 PHILIPPINES OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 694 PHILIPPINES CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 695 PHILIPPINES TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 696 PHILIPPINES MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 697 PHILIPPINES MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 698 PHILIPPINES CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 699 PHILIPPINES INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 700 PHILIPPINES OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 701 PHILIPPINES ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 702 PHILIPPINES ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 703 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 704 PHILIPPINES ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 705 PHILIPPINES TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 706 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 707 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 708 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 709 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 710 PHILIPPINES PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 711 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 712 SINGAPORE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 713 SINGAPORE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 714 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 715 SINGAPORE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 716 SINGAPORE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 717 SINGAPORE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 718 SINGAPORE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 719 SINGAPORE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 720 SINGAPORE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 721 SINGAPORE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 722 SINGAPORE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 723 SINGAPORE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 724 SINGAPORE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 725 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 726 SINGAPORE ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 727 SINGAPORE TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 728 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 729 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 730 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 731 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 732 SINGAPORE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 733 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 734 INDONESIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 735 INDONESIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 736 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 737 INDONESIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 738 INDONESIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 739 INDONESIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 740 INDONESIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 741 INDONESIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 742 INDONESIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 743 INDONESIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 744 INDONESIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 745 INDONESIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 746 INDONESIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 747 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 748 INDONESIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 749 INDONESIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 750 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 751 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 752 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 753 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 754 INDONESIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 755 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 756 VIETNAM EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 757 VIETNAM ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 758 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 759 VIETNAM OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 760 VIETNAM CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 761 VIETNAM TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 762 VIETNAM MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 763 VIETNAM MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 764 VIETNAM CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 765 VIETNAM INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 766 VIETNAM OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 767 VIETNAM ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 768 VIETNAM ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 769 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 770 VIETNAM ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 771 VIETNAM TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 772 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 773 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 774 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 775 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 776 VIETNAM PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 777 REST OF ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 778 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 779 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 780 SOUTH AMERICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 781 SOUTH AMERICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 782 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 783 SOUTH AMERICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 784 SOUTH AMERICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 785 SOUTH AMERICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 786 SOUTH AMERICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 787 SOUTH AMERICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 788 SOUTH AMERICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 789 SOUTH AMERICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 790 SOUTH AMERICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 791 SOUTH AMERICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 792 SOUTH AMERICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 793 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 794 SOUTH AMERICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 795 SOUTH AMERICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 796 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 797 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 798 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 799 SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 800 SOUTH AMERICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 801 BRAZIL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 802 BRAZIL EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 803 BRAZIL ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 804 BRAZIL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 805 BRAZIL OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 806 BRAZIL CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 807 BRAZIL TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 808 BRAZIL MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 809 BRAZIL MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 810 BRAZIL CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 811 BRAZIL INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 812 BRAZIL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 813 BRAZIL ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 814 BRAZIL ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 815 BRAZIL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 816 BRAZIL ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 817 BRAZIL TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 818 BRAZIL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 819 BRAZIL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 820 BRAZIL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 821 BRAZIL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 822 BRAZIL PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 823 ARGENTINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 824 ARGENTINA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 825 ARGENTINA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 826 ARGENTINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 827 ARGENTINA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 828 ARGENTINA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 829 ARGENTINA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 830 ARGENTINA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 831 ARGENTINA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 832 ARGENTINA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 833 ARGENTINA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 834 ARGENTINA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 835 ARGENTINA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 836 ARGENTINA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 837 ARGENTINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 838 ARGENTINA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 839 ARGENTINA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 840 ARGENTINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 841 ARGENTINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 842 ARGENTINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 843 ARGENTINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 844 ARGENTINA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 845 PERU PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 846 PERU EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 847 PERU ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 848 PERU PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 849 PERU OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 850 PERU CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 851 PERU TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 852 PERU MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 853 PERU MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 854 PERU CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 855 PERU INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 856 PERU OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 857 PERU ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 858 PERU ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 859 PERU PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 860 PERU ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 861 PERU TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 862 PERU PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 863 PERU PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 864 PERU PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 865 PERU PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 866 PERU PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 867 REST OF SOUTH AMERICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 868 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

TABLE 869 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 870 MIDDLE EAST AND AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 871 MIDDLE EAST AND AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 872 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 873 MIDDLE EAST AND AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 874 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 875 MIDDLE EAST AND AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 876 MIDDLE EAST AND AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 877 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 878 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 879 MIDDLE EAST AND AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 880 MIDDLE EAST AND AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 881 MIDDLE EAST AND AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 882 MIDDLE EAST AND AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 883 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 884 MIDDLE EAST AND AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 885 MIDDLE EAST AND AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 886 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 887 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 888 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 889 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 890 MIDDLE EAST AND AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 891 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 892 SAUDI ARABIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 893 SAUDI ARABIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 894 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 895 SAUDI ARABIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 896 SAUDI ARABIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 897 SAUDI ARABIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 898 SAUDI ARABIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 899 SAUDI ARABIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 900 SAUDI ARABIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 901 SAUDI ARABIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 902 SAUDI ARABIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 903 SAUDI ARABIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 904 SAUDI ARABIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 905 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 906 SAUDI ARABIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 907 SAUDI ARABIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 908 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 909 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 910 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 911 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 912 SAUDI ARABIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 913 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 914 SOUTH AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 915 SOUTH AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 916 SOUTH AFRICAPROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 917 SOUTH AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 918 SOUTH AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 919 SOUTH AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 920 SOUTH AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 921 SOUTH AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 922 SOUTH AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 923 SOUTH AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 924 SOUTH AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 925 SOUTH AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 926 SOUTH AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 927 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 928 SOUTH AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 929 SOUTH AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 930 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 931 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 932 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 933 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 934 SOUTH AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 935 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 936 ISRAEL EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 937 ISRAEL ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 938 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 939 ISRAEL OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 940 ISRAEL CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 941 ISRAEL TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 942 ISRAEL MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 943 ISRAEL MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 944 ISRAEL CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 945 ISRAEL INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 946 ISRAEL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 947 ISRAEL ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 948 ISRAEL ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 949 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 950 ISRAEL ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 951 ISRAEL TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 952 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 953 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 954 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 955 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 956 ISRAEL PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 957 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 958 KUWAIT EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 959 KUWAIT ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 960 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 961 KUWAIT OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 962 KUWAIT CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 963 KUWAIT TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 964 KUWAIT MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 965 KUWAIT MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 966 KUWAIT CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 967 KUWAIT INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 968 KUWAIT OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 969 KUWAIT ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 970 KUWAIT ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 971 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 972 KUWAIT ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 973 KUWAIT TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 974 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 975 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 976 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 977 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 978 KUWAIT PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 979 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 980 U.A.E EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 981 U.A.E ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 982 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 983 U.A.E OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 984 U.A.E CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 985 U.A.E TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 986 U.A.E MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 987 U.A.E MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 988 U.A.E CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 989 U.A.E INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 990 U.A.E OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 991 U.A.E ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 992 U.A.E ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 993 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 994 U.A.E ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 995 U.A.E TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 996 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 997 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 998 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 999 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 1000 U.A.E PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 1001 REST OF MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

Prophylaxis of Organ Rejection Market to grow at a CAGR of 4.4% by forecast 2029.
Prophylaxis of Organ Rejection Market value to reach USD 3,894.40 million by forecast 2029.
The countries covered in the prophylaxis of organ rejection market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Lithuania, rest of Europe in Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific(APAC) Brazil, Argentina, Peru, rest of South America in South America, South Africa, Saudi Arabia, UAE, Israel, Egypt, Kuwait and rest of Middle East and Africa in Middle East and Africa (MEA).
The major companies providing the global prophylaxis of organ rejection are Ossium Health, Inc, Alphamab Oncology, Altavant Sciences, Inc, Hansa Biopharma, Concord Biotech, Panacea Biotec, WOCKHARDT, SEBELA PHARMACEUTICALS, Accord-UK Ltd, Veloxis Pharmaceuticals, Inc, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy’s Laboratories, Ltd, Viatris Inc, Strides Pharma Science Limited, Glenmark, Biocon, Pfizer Inc, Mayne Pharma Group Limited ,Hikma Pharmaceuticals PLC, AbbVie Inc, Apotex Inc, Teva Pharmaceutical U.S.A Inc, Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Novitium Pharma, ZHEJIANG HISUN PHARMACEUTICAL Co., LTD, F. Hoffmann-La Roche Ltd, CSL Behring.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials